Company Progress - The company has made significant progress in its research pipeline, with its first global serum-free rabies vaccine successfully passing the National Medical Products Administration's registration site inspection on February 5, 2026, bringing the product closer to market launch [2] - Several key products, including the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23), are in the final stages before market launch [2] Stock Performance - Despite the advancements, the stock price of the company (06660.HK) has recently experienced a decline, closing at HKD 3.03 on February 12, 2026, down 5.90% for the day and a cumulative drop of 18.98% over the past 20 trading days [3] - The stock price fluctuations may be influenced by several factors, including the overall market environment, with the Hong Kong stock market showing volatility and the Hang Seng Index declining during the same period [3] - Short-term performance pressures are evident, with the company's revenue for the first half of 2025 at RMB 515 million, a slight decrease of 4.2% year-on-year, primarily due to a decline in revenue from its core rabies vaccine [3] - Although losses have narrowed year-on-year, short-term performance volatility may affect market sentiment, and the company continues to require ongoing investment in R&D before significant revenue contributions from new products can be realized [3]
艾美疫苗业务进展积极但股价受多重因素影响